Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response - - GEO DataSets

Summary

Format

Summary
Summary (text)
Unique Identifier List

Send to:

Choose Destination

File
Clipboard
Collections

Links from GEO Profiles

Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response

Analysis of lapatinib-resistant ErbB2-positive cells treated with 0.1 or 1 uM lapatinib. Lapatinib is an EGFR/ErbB2 inhibitor used to treat ErbB2‐positive advanced or metastatic breast cancer. Results provide insight into the mechanisms underlying the development of resistance to lapatinib.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 2 cell type, 3 dose sets

Platform:: GPL6947
Series:: GSE38376
18 Samples

Download data

DataSet

Accession:: GDS4979

ID:: 4979

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Supplemental Content

GEO DataSets

Functional Genomics Studies

Result Filters

Send to:

Links from GEO Profiles

Supplemental Content

Related information

Important Links

Recent activity